Literature DB >> 19220731

Induction of factor VIII-specific unresponsiveness by intrathymic factor VIII injection in murine hemophilia A.

S Madoiwa1, T Yamauchi, E Kobayashi, Y Hakamata, M Dokai, N Makino, Y Kashiwakura, A Ishiwata, T Ohmori, J Mimuro, Y Sakata.   

Abstract

SUMMARY
BACKGROUND: Hemophilia A is a congenital bleeding disorder caused by a deficiency of coagulation factor VIII. Approximately 30% of hemophilia A patients develop inhibitors against FVIII following replacement therapy. We have reported that neonatal exposure of FVIII antigen can induce antigen-specific immune tolerance by interferon-gamma (IFN-gamma)-dependent T-cell anergy in hemophilia A mice.
OBJECTIVE: The thymus plays crucial roles in self-tolerance, with negative selection of self-reactive effector T cells and positive selection of self-reactive regulatory T cells. We investigated the possibility of the induction of antigen-specific immune tolerance by intrathymic injection of FVIII in hemophilia A mice.
METHODS: Hemophilia A mice were injected with recombinant FVIII into the thymus under real-time high-resolution image guidance.
RESULTS: Anti-FVIII inhibitory antibody titers in mice challenged with intravenous administration of FVIII were significantly lower in mice (n = 22) that had received thymic FVIII injection than in mice (n = 18) without thymic injection (9.4 +/- 2.3 vs. 122.5 +/- 27.6 BU mL(-1), respectively, P = 0.00078). The CD4(+) T cells from thymic-injected mice could not proliferate or produce interleukin (IL)-2, IL-12 and IFN-gamma in response to FVIII. The CD4(+)CD25(+) T cells generated from thymic-treated mice but not from naïve mice efficiently suppressed the in vitro proliferative response of CD4(+) T cells and blocked the in vivo development of anti-FVIII antibodies in the adoptive transfer.
CONCLUSION: These data suggest that intrathymic administration of FVIII could result in immune tolerance by induction of FVIII-specific regulatory T cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19220731     DOI: 10.1111/j.1538-7836.2009.03314.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  7 in total

1.  Regulatory T cells and immune tolerance to coagulation factor IX in the context of intramuscular AAV1 gene transfer.

Authors:  Meagan Kelly; Arpita S Bharadwaj; Frank Tacke; Hengjun Chao
Journal:  Mol Ther       Date:  2009-11-24       Impact factor: 11.454

Review 2.  Preclinical models used for immunogenicity prediction of therapeutic proteins.

Authors:  Vera Brinks; Daniel Weinbuch; Matthew Baker; Yann Dean; Philippe Stas; Stefan Kostense; Bonita Rup; Wim Jiskoot
Journal:  Pharm Res       Date:  2013-05-07       Impact factor: 4.200

3.  Immunogenicity of protein therapeutics: The key causes, consequences and challenges.

Authors:  Matthew P Baker; Helen M Reynolds; Brooke Lumicisi; Christine J Bryson
Journal:  Self Nonself       Date:  2010-10

4.  Induction of immune tolerance to a therapeutic protein by intrathymic gene delivery.

Authors:  Qiuming Chu; Rodney J Moreland; Lan Gao; Kristin M Taylor; Elizabeth Meyers; Seng H Cheng; Ronald K Scheule
Journal:  Mol Ther       Date:  2010-07-27       Impact factor: 11.454

Review 5.  In vivo induction of regulatory T cells for immune tolerance in hemophilia.

Authors:  Xiaomei Wang; Cox Terhorst; Roland W Herzog
Journal:  Cell Immunol       Date:  2015-10-09       Impact factor: 4.868

6.  Repression of Factor VIII Inhibitor Development with Apoptotic Factor VIII-expressing Embryonic Stem Cells.

Authors:  Yoshihiko Sakurai; Shogo Kasuda; Kohei Tatsumi; Tomohiro Takeda; Junko Kato; Atsushi Kubo; Midori Shima
Journal:  Hematol Rep       Date:  2013-07-01

Review 7.  Tolerance to FVIII: Role of the Immune Metabolic Enzymes Indoleamine 2,3 Dyoxigenase-1 and Heme Oxygenase-1.

Authors:  Davide Matino; Sajjad Afraz; George Zhao; Paul Tieu; Marco Gargaro; Francesca Fallarino; Alfonso Iorio
Journal:  Front Immunol       Date:  2020-04-15       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.